Evaluating the Efficacy, Safety, and Practical Considerations of Semaglutide for Weight Loss in Non‐Diabetic Adults: A Narrative Review

ABSTRACT

Background and Aims

The rising global prevalence of obesity has catalyzed the development of potent glucagon‐like peptide‐1 (GLP‐1) receptor agonists. This narrative review evaluates the efficacy, safety, and practical considerations of injectable semaglutide for weight management, specifically in non‐diabetic adults, a population where weight loss outcomes often differ from those seen in diabetic cohorts.

Methods

Using information from PubMed, Scopus, and Web of Science, a thematic synthesis was carried out under the guidance of the SANRA procedural framework (2019–2025). The search used tirzepatide as a comparative benchmark and a particular Boolean string to target semaglutide efficacy in non‐diabetic groups. To evaluate metabolic effects and practical obstacles, data from 27 studies including observational studies, randomized controlled trials (RCTs), and qualitative reports, were analytically combined.

Results

In adults without diabetes, semaglutide (2.4 mg) shows better weight loss efficacy, with mean reductions of roughly 14.9% as opposed to 9.6% in diabetic groups. Significant improvements in cardiometabolic indicators and quality‐of‐life assessments were observed in addition to weight loss. Nevertheless, the main reason for stopping is still gastrointestinal side effects. Long‐term therapeutic utility is greatly impacted by practical obstacles, such as high out‐of‐pocket expenses, worldwide supply limitations, and the possibility of weight gain after cessation.

Conclusion

Although semaglutide is a novel obesity disease‐modifying medication, its effectiveness depends on how well it is incorporated into multimodal treatment plans. Even though its effectiveness has been shown, equitable public health implementation requires addressing structural issues and safety concerns, such as drug pricing models and insurance coverage. Long‐term durability studies and head‐to‐head trials with next‐generation incretins should be the top priorities for future research.

1. Introduction

1.1. Introduction to Obesity

Obesity is a multifactorial global health crisis characterized by excessive body fat accumulation and associated with increased morbidity and mortality. Current projections suggest that over half of the global population will be overweight or obese within the next 12 years, underscoring the urgency of effective interventions [1]. In the United States, obesity prevalence reached 41.9% in 2023, contributing to a global rate of approximately 39% [2]. Obesity is strongly linked to a range of chronic conditions, including cardiovascular disease, type 2 diabetes, hypertension, obstructive sleep apnea, and osteoarthritis [3]. While not a direct cause of mortality, its comorbidities significantly compromise health outcomes.

Beyond biomedical implications, obesity is embedded in sociocultural discourse, with phenomena such as “fat phobia” shaping public attitudes and healthcare interactions [4]. The etiology of obesity involves a complex interplay of genetic, behavioral, environmental, and physiological factors, making its management particularly challenging [5]. Multidimensional strategies incorporating clinical assessments, physical activity, and dietary modifications remain foundational.

Although behavioral interventions can enhance adherence to lifestyle changes, long‐term weight regain is common and often undermines improvements in cardio metabolic indicators [5]. Pharmacological approaches, when responsibly integrated, offer an additional avenue for addressing obesity's complexity and improving patient outcomes [6].

1.1.1. Weight Management Challenges

The etiology of obesity involves a complex interplay of genetic, behavioral, and physiological factors that make sustainable management challenging. Biological barriers are prominent; genetic predispositions influence metabolic traits [7], while hormonal imbalances involving leptin and ghrelin can disrupt caloric deficits by increasing hunger [8]. Furthermore, variations in basal metabolic rate (BMR) make standard predictive equations less accurate for individuals with obesity, complicating energy expenditure targets [9].

Beyond biology, psychological [10] and social determinants play a critical role. High‐calorie food availability and sedentary lifestyles are exacerbated by emotional eating and unrealistic weight‐ loss goals [11]. Sociocultural variables, such as healthcare bias and stigma (also known as “fat phobia”), can have a negative impact on patient‐provider relations and [12, 13] access to care. Socioeconomic gaps also limit access to appropriate eating and physical activity [14], highlighting the importance of combating structural barriers in addition to pharmacological interventions in obesity management [10, 15].

1.2. Introduction to Semaglutide

Semaglutide is a glucagon‐like peptide‐1 (GLP‐1) receptor agonist originally developed for the treatment of type 2 diabetes. It has gained widespread attention for its weight loss potential, especially following the approval of Wegovy, a higher‐dose formulation of semaglutide, by the U.S. Food and Drug Administration (FDA) in June 2021 for chronic weight management in adults with obesity or overweight and at least one weight‐related condition [3]. While Ozempic, another semaglutide‐based formulation, is FDA‐approved for glycemic control in type 2 diabetes, its use for weight loss remains off‐label [16].

1.3. Rationale for Investigating Semaglutide for Weight Loss

Obesity is a leading contributor to global morbidity and mortality, accounting for approximately 4.7 million deaths annually [17]. Traditional interventions such as lifestyle modification and older pharmacotherapies often yield limited long‐term success. Semaglutide, with its robust weight loss effects demonstrated in clinical trials, offers a promising pharmacological option for individuals seeking sustainable weight reduction, including those without diabetes.

1.4. Mechanisms of Action

1.4.1. Glucose‐Regulating Mechanisms

Semaglutide mimics the action of endogenous GLP‐1, a hormone secreted by the gut in response to food intake. By activating GLP‐1 receptors in the central nervous system and peripheral tissues, semaglutide facilitates multiple mechanisms that support weight loss [18]: GLP‐1 receptor agonist mimics the incretin hormones naturally produced in the small intestine. Its primary glucoregulatory role is achieved through glucose‐dependent insulin secretion from pancreatic beta cells. Simultaneously, it suppresses inappropriate glucagon secretion from alpha cells, thereby reducing hepatic glucose production. These actions occur primarily when blood glucose levels are elevated, minimizing the risk of hypoglycemia in non‐diabetic users [19, 20].

1.4.2. Weight‐Regulating Mechanisms

Semaglutide's effects on weight loss are mediated by several routes in the gastrointestinal tract and central nervous system. Semaglutide enters the brain across the blood‐brain barrier and targets the hypothalamus and area postrema, which are important regions for controlling hunger. It reduces hunger signals while increasing satiety (fullness) signals [18].

Semaglutide prolongs postprandial fullness and slows the pace at which nutrients enter the small intestine by delaying gastric emptying in the periphery [21]. The drug lowers total calorie intake and may affect fat metabolism and energy expenditure by modifying these brain and physical signals, which enhances its long‐term effects on weight loss.

1.5. Multisystem Effects of Semaglutide

Semaglutide exerts effects across various organ systems, contributing to its therapeutic versatility [22]:

System	Effects
Pancreas	↑ Insulin secretion, ↓ Glucagon, ↑ β‐cell proliferation
Liver	↓ Hepatic glucose production, ↑ Glycogen synthesis
CNS	↓ Appetite, ↑ Satiety, ↓ Inflammation
GI tract	↓ Gastric emptying, ↓ Acid secretion
Cardiovascular	↓ Blood pressure, ↑ Heart rate (long‐acting analogs), ↓ Ischemic injury
Kidney	↑ Sodium excretion, ↑ Urine output
Bone	↓ Bone resorption
Neural system	↑ Synaptic plasticity, ↓ Amyloid plaques

1.6. Growing Popularity and Public Interest

The use of semaglutide for weight loss has expanded rapidly, driven by clinical evidence, media coverage, and public interest. While Wegovy is approved for obesity management, the off‐label use of Ozempic for cosmetic weight loss has raised concerns about accessibility, regulatory clarity, and clinical appropriateness [23]. This trend underscores the need for balanced, evidence‐based guidance on semaglutide's role in weight management, particularly for non‐ diabetic adults. The clinical decision‐making pathway for semaglutide use in non‐diabetic adults is illustrated in Figure 1.

Figure 1.

Concept map (semaglutide clinical pathway in non‐diabetic adults).

1.7. Long‐Term Effects and Emerging Evidence on Semaglutide

Numerous studies have demonstrated the long‐term benefits of semaglutide for weight management, particularly in non‐diabetic adults. Sustained weight loss, improved metabolic parameters, and enhanced quality of life have been consistently reported across clinical trials [24]. Patients adhering to semaglutide therapy over extended periods have shown maintenance of weight reduction, with some continuing to benefit even after discontinuation [21].

Importantly, semaglutide's once‐weekly dosing regimen contributes to better adherence and treatment persistence, which are critical for long‐term success.

1.8. New Evidence: SELECT Trial and Beyond

The SELECT trial, a landmark study published in 2024, evaluated semaglutide's impact on cardiovascular outcomes and weight loss in non‐diabetic adults with obesity. Over a 4‐year period, participants experienced an average weight reduction of 10.2%, along with significant improvements in waist circumference, blood pressure, and lipid profiles [25]. The trial also reported a reduction in major adverse cardiovascular events compared to placebo, reinforcing semaglutide's potential beyond weight loss.

1.9. Long‐Term Sustainability and Weight Regain

While semaglutide demonstrates robust initial efficacy, weight regain following discontinuation remains a concern. Some studies suggest that without continued pharmacological or behavioral support, patients may regain a portion of lost weight over time. This underscores the importance of integrating semaglutide into comprehensive treatment plans that include lifestyle modification, nutritional counseling, and psychological support.

1.10. Comparative Effectiveness and Limitation to Other Drugs

Compared to older anti‐obesity medications such as orlistat, semaglutide, and newer agents like tirzepatide offer greater weight loss and improved tolerability [26]. However, cost, accessibility, and long‐term safety data remain limiting factors. Semaglutide's favorable profile in terms of efficacy and adherence positions it as a leading option, but ongoing research is needed to optimize its use across diverse populations.

1.11. Potential Additional Benefits

Beyond weight loss, semaglutide has shown promise in reducing the risk of type 2 diabetes, cardiovascular disease, and certain cancers [3]. Its anti‐inflammatory and metabolic effects may contribute to broader health improvements, making it a candidate for multi‐morbidity management in obese individuals.

2. Methodology

2.1. Review Design

This study is a narrative review designed to synthesize recent evidence regarding semaglutide's efficacy, safety, and clinical application in non‐diabetic adults. Unlike a systematic review, this format allows for an exploratory synthesis of both trial‐based and real‐world data. The synthesis was guided by the following specific research questions:

• 1.What is the comparative efficacy of various injectable semaglutide doses for weight reduction in adults without type 2 diabetes?
• 2.What are the most prevalent and clinically significant adverse effects and safety concerns associated with long‐term use?
• 3.What practical barriers including cost, adherence, and structural determinants— influence the real‐world utility of these agents?

2.2. Operationalization of SANRA

While the Scale for the Assessment of Narrative Review Articles (SANRA) is primarily an assessment tool for editors, it was operationalized here as a procedural framework to ensure methodological rigor. By systematically applying the six SANRA criteria (justification of importance, statement of aims, search strategy description, referencing, scientific reasoning, and data presentation), we ensured that this synthesis maintains the transparency and logic expected in high‐level clinical reviews.

2.3. Data Sources and Search Strategy

A comprehensive literature search was conducted across PubMed, Scopus, Web of Science, and Google Scholar for studies published between January 2019 and May 2025. Filters were applied to restrict results to English‐language publications and human subjects.

2.3.1. Complete Search String

(“Semaglutide”[Mesh] OR “GLP‐1 Receptor Agonists”[Mesh] OR “Semaglutide” OR “Wegovy” OR “Ozempic”) AND (“Obesity”[Mesh] OR “Weight Loss”[Mesh] OR “Overweight”) AND (“Non‐diabetic”) NOT (“Diabetes Mellitus, Type 2”[Mesh]).

2.3.2. Justification for Tirzepatide Inclusion

Although tirzepatide was not the primary focus of the inclusion criteria, it was included in the search strategy to identify head‐to‐head comparative trials and to provide a necessary benchmark for “next‐generation” therapies. This allows for a more robust analysis of semaglutide's current standing within the rapidly evolving pharmacological landscape of obesity management.

2.4. Analytical Integration of Evidence

Evidence from diverse study types was integrated using a thematic synthesis approach. Data from Randomized Controlled Trials (RCTs) (e.g., the STEP and SELECT programs) established the “gold standard” for efficacy and safety. Observational and real‐world studies were utilized to contextualize these findings within clinical practice, specifically regarding adherence. Finally, qualitative data were integrated to capture “practical considerations,” such as stigma and psychosocial impacts, ensuring a holistic view of the treatment landscape.

2.5. Inclusion and Exclusion Criteria

Criteria	Included Studies
Population	Adults aged ≥ 18 years, non‐diabetic, with overweight or obesity
Intervention	Semaglutide (injectable) for weight loss
Comparators	Placebo, lifestyle interventions, or other anti‐obesity drugs
Outcomes	Weight change, BMI, metabolic outcomes, side effects, adherence
Study Types	Randomized controlled trials (RCTs), meta‐analyses, large observational studies

Exclusion:

• Studies focused exclusively on type 2 diabetic populations.

• Oral semaglutide formulations.

• Pediatric or adolescent studies.

• Non‐human or preclinical trials.

• Opinion articles, editorials, or case reports unless relevant to emerging concerns (e.g., cosmetic effects).

2.6. Study Selection Process

A total of 112 studies were initially identified. After removing 15 duplicates, 97 titles and abstracts were screened. Of these, 42 full texts were assessed, and 27 studies met the final inclusion criteria. The process of study identification and selection is summarized in Figure 2.

Figure 2.

Study selection flowchart.

3. Results

3.1. Study Selection

A total of 112 records were identified from PubMed, Scopus, and Web of Science. After duplicate removal and screening, 27 articles met the inclusion criteria, comprising RCTs, meta‐analyses, observational studies, and real‐world analyses evaluating semaglutide's weight loss efficacy, safety, adherence, and economic impact in non‐ diabetic adults.

3.2. Efficacy of Semaglutide

3.2.1. Wegovy (2.4 mg/week)

Clinical trials such as the STEP and SELECT programs have consistently demonstrated the efficacy of semaglutide 2.4 mg/week (Wegovy) in promoting significant weight loss in non‐ diabetic individuals with obesity. For instance, the SELECT trial reported a mean weight reduction of 10.2% sustained over 4 years [25], while STEP 1 and 3 trials showed average losses of 14.9% and 16%, respectively [24, 26]. Improvements were also noted in waist circumference, blood pressure, and lipid parameters. The comparative efficacy and regulatory status of various semaglutide formulations are summarized in Table 1 below.

Table 1.

Comparative efficacy, dosing, and regulatory status of studied semaglutide formulations for weight loss in non‐diabetic populations.

Agent	Studied dose	Avg. weight loss	Duration	Primary side effects	Regulatory status for obesity
Wegovy	2.4 mg/week	10%–16% [25]	40–68 weeks	Nausea, vomiting, fatigue [18]	FDA approved [19]
Ozempic	1.0 mg/week	5%–11% [21]	24–52 weeks	Nausea, headache, constipation [21, 23]	Off‐label [24]
Liraglutide	3.0 mg/day	8%–10% [25]	56 weeks	Nausea, constipation [26]	FDA approved [20]

3.2.2. Ozempic (1 mg/week)

Although Ozempic is not approved for obesity, several studies have evaluated its off‐label use. A recent review reported weight loss of 5%–7% of baseline weight over 24–52 weeks in non‐diabetic populations using semaglutide 1 mg/week [21, 27]. However, this lower dose is less effective than Wegovy, and results vary depending on patient characteristics and adherence [28]_.

As noted by Kute et al. [18], misuse of both Wegovy and Ozempic in aesthetic and weight‐loss clinics contributes to confusion regarding efficacy claims outside their approved indications.

3.2.3. Adverse Effects and Safety

Semaglutide is generally well tolerated, but side effects are dose‐dependent:

• Gastrointestinal (GI) Symptoms:

• ∘Nausea (20%–44%).
• ∘Diarrhea (15%–30%).
• ∘Constipation (~15%).
• ∘These were the most frequently reported across trials [21, 26], and [27].

• Pancreatitis and Gallbladder Disease:

  Cases of acute pancreatitis and cholelithiasis have been reported, particularly in patients with rapid weight loss or pre‐existing risk factors [26, 29].

• Thyroid Concerns:

• Preclinical studies reported medullary thyroid carcinoma in rodents, but no human causal evidence has been confirmed [29].

• Emerging Concerns:

• 1.Facial lipoatrophy (colloquially referred to as “Ozempic Face”) has been described in aesthetic case reports and specialty clinics due to rapid subcutaneous fat loss [30].
• 2.Sexual Dysfunction: A TriNetX database study found a potential link between semaglutide and erectile dysfunction in non‐diabetic males [31].
• 3.Delayed Inflammatory Reactions: Noted in patients with dermal fillers, as reported in craniofacial surgery case reports [32].

These emerging issues require further validation but have significant patient counseling implications.

3.3. Weight Regain After Discontinuation

Weight regain is a significant concern following semaglutide discontinuation. In studies where the drug was stopped, patients regained approximately two‐thirds of the weight lost within 12 months, emphasizing the need for ongoing support and maintenance plans [24, 25]. This phenomenon underscores that semaglutide is not a cure but part of a chronic management strategy for obesity.

3.4. Patient Adherence and Persistence

In real‐world studies, semaglutide shows moderate long‐term adherence. Gleason et al. [33] reported a 12‐month persistence rate of 47.1% among commercially insured non‐diabetic adults. Dropouts were primarily linked to side effects, cost, and injection fatigue [34]. Public and online discourse also reflects rising dissatisfaction with semaglutide discontinuation and regain, as documented in qualitative analyses of social media and forums [4, 23].

3.5. Economic and Practical Considerations

The cost of semaglutide remains a major barrier. Comparative models indicate that semaglutide is less cost‐effective than endoscopic bariatric procedures such as ESG (endoscopic sleeve gastroplasty), unless long‐term benefits are sustained [28]. In the UK, reports from the NHS cite delays and accessibility issues due to inconsistent supply and insurance restrictions [35].

3.6. Summary Table: Weight Loss Efficacy by Formulation

A summary of weight loss efficacy and side effects across formulations is presented in Table 2.

Table 2.

Weight loss efficacy by formulation.

Agent	Dose	Avg. weight loss	Duration	Common side effects	Regulatory status
Wegovy	2.4 mg/week	10%–16%	40–68 weeks	Nausea, diarrhea, fatigue	Approved for obesity
Ozempic	1 mg/week	5%–7%	24–52 weeks	Nausea, headache, constipation	Approved for T2DM (off‐label for weight loss)
Placebo	—	< 2%	—	—	Not applicable

Source: Data compiled from references [21, 24, 25, 26, 28, 31, 33] and [27].

4. Discussion

4.1. Summary of Evidence

Semaglutide, a GLP‐1 receptor agonist, has emerged as a potent pharmacologic intervention for weight loss in non‐diabetic adults with obesity. At the 2.4 mg/week dose (Wegovy), semaglutide demonstrated clinically significant weight reductions of 10%–16%, sustained over several years, as evidenced by the SELECT and STEP trials [24, 25, 26]. These outcomes are superior to those of older anti‐obesity medications and are accompanied by favorable metabolic improvements. A comparative overview of semaglutide and other anti‐obesity agents [36] is shown in Table 3.

Table 3.

Comparative efficacy and side effect profiles of anti‐obesity medications approved for long‐term use.

Agent	Average weight loss	Duration	Common side effects	Regulatory status
Wegovy	14.9%	68 weeks	Nausea, vomiting, fatigue	Approved for obesity
Ozempic	9%–11%	40–52 weeks	Nausea, diarrhea, headache	Approved for type 2 diabetes
Orlistat	5%–7%	24–52 weeks	Oily stools, flatulence	Approved for obesity
Liraglutide	8%–10%	56 weeks	Nausea, headache, constipation	Approved for obesity

Source: STEP trials, FDA drug labels, and comparative pharmacotherapy reviews.

4.1.1. Comparison to Diabetic Populations

Notably, semaglutide's effectiveness in helping people lose weight is noticeably greater in non‐diabetics than in people with type 2 diabetes (T2DM). Diabetic cohorts in the STEP 2 study experienced a relatively modest weight loss of about 9.6% at the same 2.4 mg dose, but non‐diabetic individuals in the STEP 1 trial obtained a mean weight loss of about 14.9%. This “weight loss gap” is probably caused by T2DM's complex metabolic and insulin‐resistant conditions, which may lessen the anorexic response to GLP‐1 receptor agonists. As a result, even while semaglutide is beneficial for both groups, non‐diabetic adults usually lose a larger proportion of their body weight overall, highlighting the medication's effective function as a primary anti‐obesity strategy.

However, the growing body of evidence reveals a wider safety and practical profile. While gastrointestinal side effects such as nausea, diarrhea, and constipation are common [21, 26], more nuanced adverse events have emerged. These include facial lipoatrophy (colloquially termed ‘Ozempic Face’), erectile dysfunction, and inflammatory filler reactions, which, although not universally reported, warrant consideration and monitoring [30, 31, 32]. The risk of weight regain upon discontinuation adds further complexity to long‐term care planning [24]. Thus, while the benefits are promising, risk‐benefit assessment must be individualized, particularly when used off‐label (e.g., Ozempic for weight loss) [18, 28].

4.2. Strengths and Limitations

A key strength of this review lies in its synthesis of both trial‐based and real‐world evidence, including recent studies and safety concerns not widely reported in earlier reviews [18, 21, 23]. The inclusion of qualitative data (e.g., online public discussions) provides insight into user perceptions, adherence behavior, and the social impact of semaglutide usage [4, 23].

However, limitations exist:

• The review does not include a formal meta‐analysis, limiting pooled effect size estimation. Additionally, as a narrative review, the absence of quantitative synthesis (e.g., meta‐analysis) limits the ability to generate pooled estimates and restricts the strength of evidence compared to systematic reviews.

• Several included studies are industry‐sponsored, potentially introducing publication bias [26].

• Real‐world data on long‐term adherence and safety are still emerging, with much of it based on insurance claims or anecdotal reports [33].

• Reports of cosmetic and sexual side effects are derived mainly from case series or observational studies, requiring cautious interpretation [30, 31] and [32].

4.3. Clinical Implications

Semaglutide, especially at the 2.4 mg/week dose, should be used as a second‐line treatment for individuals who have serious obesity‐related comorbidities or when lifestyle management has failed. Improving clinical outcomes and long‐term sustainability requires its incorporation into multimodal care, which includes behavioral therapy, physical exercise, nutritional counseling, and strong social support [20, 21, 26] and [27]. To ensure scientific and regulatory accuracy in prescribing, doctors must be vigilant in differentiating between formulations that have been investigated and those that have been expressly approved for obesity.

Patient education must progress beyond simple efficacy expectations to address the many practical aspects of therapy, such as self‐injection techniques, the cumulative adherence burden, and potential psychosocial effects, such as body image dissatisfaction caused by rapid facial volume loss. Recent research indicates that negative sentiments of GLP‐1 receptor agonists are primarily impacted by worries about side effects, expensive out‐of‐pocket expenditures, and limited accessibility [37].

Semaglutide's clinical utility is limited by significant structural barriers, including high costs and inconsistent global access, predominantly affecting high‐income patients. Pivotal studies have often been industry‐sponsored, necessitating independent long‐term trials to address potential bias. These economic and evidence‐based factors should be considered when integrating semaglutide into obesity management to promote equitable, evidence‐driven care.

4.4. Future Scope

Even though semaglutide is a significant development in metabolic medicine, more study is necessary to maximize its long‐term use in the treatment of persistent obesity. In order to establish a clear clinical hierarchy and assess cost‐effectiveness in comparison to bariatric therapy, future research goals must include head‐to‐head comparative trials comparing semaglutide and next‐generation incretin‐based medicines, such as tirzepatide and retatrutide [28].

Furthermore, extended safety surveillance is essential to monitor emergent concerns identified in real‐world data, such as sexual dysfunction, thyroid neoplasia, and delayed inflammatory reactions [29, 31, 32]. As obesity becomes more widely recognized as a chronic disorder, it is vital to establish evidence‐based post‐discontinuation maintenance methods. This includes identifying pharmacological or lifestyle therapies that are expressly intended to avoid rebound weight gain. Long‐term trials are still needed to assess the long‐term efficacy of these medicines for weight loss and cardio‐metabolic benefits [38].

Lastly, identifying high‐responders based on metabolic, behavioral, or genetic profiles will require a shift toward customized treatment [15, 39]. Semaglutide can be reframed as a long‐term disease‐modifying agent within a comprehensive and customized treatment paradigm for obesity by incorporating it into larger multi‐morbidity frameworks that target illnesses like PCOS, cardiovascular disease, and metabolic syndrome [26, 40], and [39].

5. Conclusion

This review confirms that semaglutide is a highly effective pharmacological intervention for weight loss in non‐diabetic adults, meeting the primary efficacy benchmarks with consistent and clinically meaningful weight reduction and improved cardio‐metabolic outcomes. These findings position the therapy as a significant tool in modern obesity management, with potential cardiovascular benefits that extend its relevance beyond simple weight control.

In terms of safety, while semaglutide has a tolerable profile, its long‐term therapeutic value is dependent on proactive control of gastrointestinal side effects and a good knowledge of the physiological causes of weight regain upon withdrawal. Ensuring patient safety necessitates a comprehensive approach that incorporates medication within multimodal frameworks such as behavioral support and continuous clinical monitoring.

From a practical consideration, the significant barriers of high cost and inconsistent global availability remain the primary hurdles to widespread implementation. To optimize the public health impact of semaglutide, future health policies must prioritize equitable access through the development of sustainable insurance coverage models and transparent drug pricing structures.

Reframing obesity as a chronic, lifelong condition demands a transition toward patient‐centered techniques and policy‐driven solutions to ensure that these metabolic advancements are both accessible and effective over the long term.

Author Contributions

Ayesha Laraib: conceptualization, writing – original draft, writing – review and editing, visualization, formal analysis, supervision. Uswa Ahmad: writing – original draft, visualization, formal analysis, data curation. Syeda Iman Laraib: validation, formal analysis, supervision, writing – original draft. Syeda Wardah Laraib: writing – original draft, writing – review and editing, visualization. Masab Ali: writing – review and editing, formal analysis, supervision, visualization, validation. Muhammad Husnain Ahmad: formal analysis, supervision, software. Muhammad Hassan: writing – original draft, writing – review and editing, visualization, validation.

Funding

The authors received no specific funding for this work.

Disclosure

All authors have read and approved the final version of the manuscript. Muhammad Husnain Ahmad (Corresponding author) had full access to all of the data in this study and takes complete responsibility for the integrity of the data and the accuracy of the data analysis. The lead author Muhammad Husnain Ahmad affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

Ethics Statement

The authors have nothing to report.

Conflicts of Interest

The authors declare no conflicts of interest.

Scope of Our Study

The study aims to evaluate the effectiveness of semaglutide for weight loss in non‐ diabetic adults, based on the latest clinical research. It seeks to provide a comprehensive overview of semaglutide's safety and potential adverse effects for individuals without diabetes. The study will also compare the safety profile of semaglutide with other weight loss medications to offer insight into its relative safety. Practical concerns such as patient adherence, dosage, administration, and cost will be discussed to make the findings relevant for both healthcare providers and patients.Additionally, the study will identify gaps in current research and propose future directions for further investigation to enhance understanding and treatment effectiveness.

Transparency Statement

The lead author Muhammad Husnain Ahmad affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

Data Availability Statement

The authors confirm that the data supporting the findings of this study are available within the article and its cited references.